After establishing a therapeutic benefit of roflumilast and Compound 1 in reducing type II AEC‐injury‐induced fibrosis, we next compared the efficacy of PDE4 inhibition to treatment with the two FDA‐approved drugs for IPF (pirfenidone and nintedanib). Here, PDE4A is linked to fibrosis.